A Study of Irinotecan Liposome in Advanced Pancreatic Cancer

A Phase I Study to Evaluate the Safety and Tolerability of Irinotecan Liposome in Combination With Oxaliplatin and 5-FU/LV in the Treatment of Advanced Pancreatic Cancer

To determine the safety and tolerability of irinotecan liposome in combination with oxaliplatin and 5-FU/LV in subjects with advanced pancreatic cancer who have not received prior systemic chemotherapy

Study Overview

• Status: Completed
• Conditions: Advanced Pancreatic Cancer
• Intervention / Treatment: Drug: Irinotecan liposome；oxaliplatin；5-FU(Fluorouracil Injection)；LV(Calcium Folinate Injection)

• Study Type: Interventional
• Enrollment (Actual): 41
• Phase: Phase 1

Contacts and Locations

Study Locations

• China
  • Beijing
    • Beijing, Beijing, China, 100730
      • Peking Union Medical College Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 70 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Males and females aged 18 to 70 years (including 18 and 70 years);
2. Patients with histologically or cytologically diagnosed pancreatic cancer (from pancreatic ductal epithelium), and clinical records show unresectable locally advanced or metastatic pancreatic cancer (stage III/IV based on the 8th Edition of the AJCC TNM staging for pancreatic cancer).
3. Have not received systemic anti-tumor therapy for the current stage of disease, including surgery (except stent placement), radiotherapy, chemotherapy, targeted therapy, immunotherapy or investigational therapy;
4. If the subject has previously received adjuvant chemotherapy, it is necessary to ensure that the time interval between the last dose and the first dose of this study is more than 12 months, and the adjuvant therapy-toxicity has recovered (judged as ≤ grade 1 based on CTCAE 5.0 criteria);
5. Must have at least one measurable lesion that can be taken as the target lesion (according to the RECIST v1.1 criteria);
6. Eastern Cooperative Oncology Group (ECOG) performance status score: 0 - 1 point;
7. Expected survival ≥3 months;
8. Major organs are functioning well

Exclusion Criteria:

1. Patients with pancreatic cancer originating from extrapancreatic ductal epithelium, including pancreatic neuroendocrine carcinoma, acinar cell carcinoma of the pancreas, pancreatoblastoma, and solid-pseudopapillary tumor;
2. Patients with known central nervous system metastases;
3. Patients carrying homozygous mutations of UGT1A1*28/*6 gene;
4. Severe gastrointestinal dysfunction;
5. Severe infection (> CTCAE grade 2), such as severe pneumonia, bacteremia, infection complications, etc. requiring inpatient treatment, occurred within four weeks before enrollment, and symptoms and signs of infection requiring intravenous antibiotic therapy (except for prophylactic antibiotics) occurred within two weeks before enrollment;
6. Received any of the following treatments:

1）Previously received treatment with irinotecan-containing regimens; 2）Received concomitant medications containing strong inhibitors/strong inducers of CYP3A4 or strong inhibitors of UGT1A1 within two weeks before enrollment; 3）Received the last anti-cancer treatment (including surgery, radiotherapy, etc.) within four weeks before enrollment; 4）Have received treatment with any other investigational drug/device within four weeks before enrollment; 5）Enrolled in another clinical study at the same time unless it is an observational (non-interventional) clinical study or an interventional clinical study follow-up.

7.Having experienced an arteriovenous thrombotic event, such as cerebrovascular accident, deep vein thrombosis and pulmonary embolism, within one year before enrollment; 8.Patients with cardiac clinical symptoms or diseases that are not well controlled, such as: (1) Patients with NYHA class 2 and above cardiac failure; (2) unstable angina; (3) myocardial infarction that occurred within one year; (4) clinically significant supraventricular or ventricular arrhythmia requiring treatment or intervention.

9.Patients who have suffered from malignant tumors other than pancreatic cancer before using the study drug for the first time, except those with low risk of metastasis and death (5-year survival rate >90%), such as adequately treated cervical carcinoma in situ, basal cell or squamous cell carcinoma of the skin; 10.Have any contraindication to either irinotecan liposome, irinotecan, 5-FU, calcium folinate, or oxaliplatin;

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: Irinotecan liposome；oxaliplatin；5-FU(Fluorouracil Injection)；LV(Calcium Folinate Injection); irinotecan liposome: irinotecan liposome injection is irinotecan encapsulated in liposomes for i.v. infusion.; oxaliplatin: oxaliplatin is a sterile, aqueous solution; 50mg/vial.; 5-FU(Fluorouracil Injection): an aqueous, sterile, nonpyrogenic injectable solution available in 10ml/0.25g.; LV(Calcium Folinate Injection): be supplied in vials containing 10ml/0.1g and available as an injectable solution.

Drug: Irinotecan liposome；oxaliplatin；5-FU(Fluorouracil Injection)；LV(Calcium Folinate Injection); irinotecan liposome in combination with oxaliplatin and 5-FU/LV

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
MTD	Maximum tolerated dose for patients in combination treatment.	18 months
RP2D	Recommended phase II dose for patients in combination treatment.	18 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Frequency and severity of AEs/SAEs as Assessed by CTCAE v5.0	Through laboratory test, physical examination, vital signs,12-lead electrocardiogram (ECG), Echocardiogram, etc.;	From first dose to death; until the data cut off 18 months after the last subject is enrolled. The minimum time in follow up was 18 months.
Objective Response Rate (ORR)	Number of reported responses (complete [CR] and partial [PR]) divided by the number of reported assessable patients.	From first dose to death; until the data cut off 18 months after the last subject is enrolled. The minimum time in follow up was 18 months.
Disease Control Rate (DCR)	Based on investigator reviewed radiographic tumour assessment and death.	From first dose to death; until the data cut off 18 months after the last subject is enrolled. The minimum time in follow up was 18 months
Duration of Response (DoR)	Based on investigator reviewed radiographic tumour assessment and death.	From first dose to death; until the data cut off 18 months after the last subject is enrolled. The minimum time in follow up was 18 months.
Progression-Free Survival (PFS)	Based on change in tumour per Response Evaluation Criteria in Solid Tumours (RECIST) 1.1	From first dose to death; until the data cut off 18 months after the last subject is enrolled. The minimum time in follow up was 18 months.
Overall Survival (OS)	Based on investigator reviewed radiographic tumor assessment and death.	From first dose to death; until the data cut off 18 months after the last subject is enrolled. The minimum time in follow up was 18 months.
Cmax	peak plasma concentration	28days
Tmax	time to peak concentration	28days
AUC	area under the plasma concentration versus time curve	28days
t1/2z	elimination half-life	28days
Vss	steady-state apparent volume of distribution	28days
CL	clearance	28days

Collaborators and Investigators

• Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Study record dates

Study Major Dates

• Study Start (Actual): April 8, 2021
• Primary Completion (Actual): June 28, 2024
• Study Completion (Actual): June 28, 2024

Study Registration Dates

• First Submitted: March 8, 2021
• First Submitted That Met QC Criteria: March 12, 2021
• First Posted (Actual): March 15, 2021

Study Record Updates

• Last Update Posted (Actual): April 29, 2025
• Last Update Submitted That Met QC Criteria: April 28, 2025
• Last Verified: April 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Endocrine System Diseases; Neoplasms by Site; Neoplasms; Digestive System Neoplasms; Digestive System Diseases; Endocrine Gland Neoplasms; Pancreatic Diseases; Pancreatic Neoplasms; Calcium-Regulating Hormones and Agents; Antineoplastic Agents; Immunosuppressive Agents; Immunologic Factors; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Antimetabolites, Antineoplastic; Antimetabolites; Micronutrients; Topoisomerase I Inhibitors; Topoisomerase Inhibitors; Protective Agents; Antidotes; Vitamin B Complex; Vitamins; Oxaliplatin; Irinotecan; Calcium; Fluorouracil; Leucovorin; Levoleucovorin
• Other Study ID Numbers: HR-YLTKL-101

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No